Deconstructing Olfactory Epithelium Developmental Pathways in Olfactory Neuroblastoma.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
06 2023
Historique:
received: 05 01 2023
revised: 13 03 2023
accepted: 11 05 2023
medline: 30 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Olfactory neuroblastoma is a rare tumor arising from the olfactory cleft region of the nasal cavity. Because of the low incidence of this tumor, as well as an absence of established cell lines and murine models, understanding the mechanisms driving olfactory neuroblastoma pathobiology has been challenging. Here, we sought to apply advances from research on the human olfactory epithelial neurogenic niche, along with new biocomputational approaches, to better understand the cellular and molecular factors in low- and high-grade olfactory neuroblastoma and how specific transcriptomic markers may predict prognosis. We analyzed a total of 19 olfactory neuroblastoma samples with available bulk RNA-sequencing and survival data, along with 10 samples from normal olfactory epithelium. A bulk RNA-sequencing deconvolution model identified a significant increase in globose basal cell (GBC) and CD8 T-cell identities in high-grade tumors (GBC from ∼0% to 8%, CD8 T cell from 0.7% to 2.2%), and significant decreases in mature neuronal, Bowman's gland, and olfactory ensheathing programs, in high-grade tumors (mature neuronal from 3.7% to ∼0%, Bowman's gland from 18.6% to 10.5%, olfactory ensheathing from 3.4% to 1.1%). Trajectory analysis identified potential regulatory pathways in proliferative olfactory neuroblastoma cells, including PRC2, which was validated by immunofluorescence staining. Survival analysis guided by gene expression in bulk RNA-sequencing data identified favorable prognostic markers such as SOX9, S100B, and PLP1 expression. Our analyses provide a basis for additional research on olfactory neuroblastoma management, as well as identification of potential new prognostic markers.

Identifiants

pubmed: 37377616
doi: 10.1158/2767-9764.CRC-23-0013
pii: CRC-23-0013
pmc: PMC10243222
doi:

Substances chimiques

RNA 63231-63-0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

980-990

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM007171
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM145449
Pays : United States

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Références

Adv Anat Pathol. 2009 Sep;16(5):322-31
pubmed: 19700942
Laryngoscope. 2022 Feb;132(2):290-297
pubmed: 34272876
CA Cancer J Clin. 2023 Jan;73(1):72-112
pubmed: 35916666
Laryngoscope. 2011 Aug;121(8):1687-701
pubmed: 21792956
World Neurosurg. 2020 Mar;135:e187-e193
pubmed: 31785431
Cancer. 1994 May 15;73(10):2556-62
pubmed: 8174053
Cell Stem Cell. 2017 Jun 1;20(6):817-830.e8
pubmed: 28506465
J Comp Neurol. 1998 Nov 2;400(4):469-86
pubmed: 9786409
Laryngoscope Investig Otolaryngol. 2021 Jun 07;6(4):721-728
pubmed: 34401496
J Clin Invest. 2022 Feb 15;132(4):
pubmed: 34990409
J Neurosci. 2011 May 4;31(18):6915-27
pubmed: 21543621
J Biochem. 2021 Sep 22;170(1):1-4
pubmed: 33479735
Clin Cancer Res. 2019 Dec 15;25(24):7331-7339
pubmed: 31471312
Sci Transl Med. 2022 Dec 21;14(676):eadd0484
pubmed: 36542694
Nat Methods. 2022 Mar;19(3):296-306
pubmed: 35277705
Trends Biochem Sci. 2019 Aug;44(8):688-700
pubmed: 31085088
Genome Res. 2021 Oct;31(10):1794-1806
pubmed: 34301624
Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8
pubmed: 9588546
Neuron. 1994 Aug;13(2):339-52
pubmed: 8060615
Nat Neurosci. 2020 Mar;23(3):323-326
pubmed: 32066986
JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1124-9
pubmed: 25356502
Head Neck Pathol. 2015 Mar;9(1):51-9
pubmed: 24806334
Laryngoscope Investig Otolaryngol. 2018 Sep 17;3(5):337-344
pubmed: 30410986
Neurosurg Clin N Am. 2013 Jan;24(1):51-65
pubmed: 23174357
Chem Senses. 1994 Dec;19(6):671-82
pubmed: 7735846
N Engl J Med. 1982 Jul 15;307(3):159-61
pubmed: 7201076
Development. 2016 Dec 1;143(23):4394-4404
pubmed: 27789621
Am J Surg Pathol. 2020 Mar;44(3):396-405
pubmed: 31876581
Mol Cell. 2018 May 3;70(3):408-421.e8
pubmed: 29628311
BMC Genomics. 2016 Aug 11;17(1):619
pubmed: 27515280
J Neurooncol. 1995 Oct;26(1):35-43
pubmed: 8583243
Lancet Oncol. 2001 Nov;2(11):683-90
pubmed: 11902539
Glia. 2003 Feb;41(3):224-36
pubmed: 12528178
Nat Cell Biol. 2022 Mar;24(3):384-399
pubmed: 35210568
Brain. 2000 Aug;123 ( Pt 8):1581-8
pubmed: 10908188
Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8
pubmed: 16490869
Cancer. 1976 Mar;37(3):1571-6
pubmed: 1260676
Trends Cell Biol. 2019 Aug;29(8):660-671
pubmed: 31178244
Cell Rep. 2018 Oct 16;25(3):811-821.e5
pubmed: 30332658

Auteurs

John B Finlay (JB)

Medical Scientist Training Program, Duke University School of Medicine, Durham, North Carolina.
Department of Head and Neck Surgery & Communication Sciences, Duke University, School of Medicine, Durham, North Carolina.
Department of Cell and Molecular Biology, Duke University School of Medicine, Durham, North Carolina.

Ralph Abi Hachem (R)

Department of Head and Neck Surgery & Communication Sciences, Duke University, School of Medicine, Durham, North Carolina.

David W Jang (DW)

Department of Head and Neck Surgery & Communication Sciences, Duke University, School of Medicine, Durham, North Carolina.

Nosayaba Osazuwa-Peters (N)

Department of Head and Neck Surgery & Communication Sciences, Duke University, School of Medicine, Durham, North Carolina.

Bradley J Goldstein (BJ)

Department of Head and Neck Surgery & Communication Sciences, Duke University, School of Medicine, Durham, North Carolina.
Department of Cell and Molecular Biology, Duke University School of Medicine, Durham, North Carolina.
Department of Neurobiology, Duke University School of Medicine, Durham, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH